StockNews.com started coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a report issued on Monday morning. The brokerage issued a hold rating on the stock. A number of other research analysts have also recently commented on JNCE. Piper Sandler cut shares of Jounce Therapeutics from an overweight rating to a neutral rating […]
StockNews.com assumed coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report released on Monday morning. The brokerage issued a hold rating on the stock. Several other research firms have also issued reports on JNCE. Sumitomo Mitsui Financial Group reissued a neutral rating on shares of Jounce Therapeutics in a report […]
Stock analysts at StockNews.com assumed coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock. JNCE has been the subject of several other reports. Piper Sandler cut Jounce Therapeutics from an “overweight” rating to a […]
Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) was the recipient of a large drop in short interest in April. As of April 15th, there was short interest totalling 2,020,000 shares, a drop of 11.4% from the March 31st total of 2,280,000 shares. Based on an average trading volume of 2,640,000 shares, the days-to-cover ratio is […]
StockNews.com started coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the stock. A number of other analysts have also weighed in on the stock. Sumitomo Mitsui Financial Group restated a neutral rating on shares of Jounce […]